Statins: A perspective for left ventricular hypertrophy treatment

European Journal of Clinical Investigation

Volumn 37, Issue 9, 2007, Pages 681-691

  Simko, F ^a  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

Author keywords

Left ventricular hypertrophy; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; GROWTH FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METHYLDOPA; MEVINOLIN; NEUROHORMONE; NITRIC OXIDE; PITAVASTATIN; PRAVASTATIN; RAS PROTEIN; RHO FACTOR; SIMVASTATIN;

AORTA STENOSIS; CAPILLARY DENSITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; DRUG MECHANISM; DYSLIPOPROTEINEMIA; ESSENTIAL HYPERTENSION; GENE EXPRESSION; HEART ELECTROPHYSIOLOGY; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HORMONE SYNTHESIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; TRANSGENIC ANIMAL; WEIGHT REDUCTION;

ANIMALS; GTP-BINDING PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTROPHY, LEFT VENTRICULAR; MODELS, ANIMAL; RATS;

EID: 34547887250     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01837.x     Document Type: Review

References (123)

1. Grossman W. Cardiac hypertrophy: useful adaptation or pathologic process? Am J Med 1980 69 : 576 84.
2. Weber KT. Cardioreparation in hypertensive heart disease. Hypertension 2001 38 : 588 91.
3. Simko F, Pechanova O, Bernatova I, Gvozdjakova A, Kucharska J, Hulin I et al. Effect of captopril on the development of left ventricular hypertrophy in rabbits with aortic insufficiency. Physiol Res 1997 46 : 419 25.
4. Simko F, Matuskova J, Luptak I, Krajcirovicova K, Kucharska J, Gvozdjakova A et al. Effect of simvastatin on remodelling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci 2004 74 : 1211 24.
5. Simko F, Luptak I, Matuskova J, Krajcirovicova K, Sumbalova Z, Kucharska J et al. 1-arginine fails to protect against myocardial remodelling in L-NAME-induced hypertension. Eur J Clin Invest 2005 35 : 362 8.
6. Pechanova O, Bernatova I, Pelouch V, Simko F. Protein remodelling of the heart in NO-deficient hypertension: the effect of captopril. J Mol Cell Cardiol 1997 29 : 3365 74.
7. Bernatova I, Pechanova O, Simko F. Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney. Exp Physiol 1999 84 : 1095 105.
8. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection and prognosis. Circulation 2000 102 : 470 9.
9. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004 292 : 2350 6.
10. Tarazi RC, Frohlich ED. Is reversal of cardiac hypertrophy a desirable goal of antihypertensive therapy? Circulation 1987 75 (Suppl. I I 113 7.
11. Phillips RA. Etiology, pathophysiology, and treatment of left ventricular hypertrophy: focus on severe hypertension. J Cardiovasc Pharmacol 1993 21 (Suppl. 2 S55 62.
12. Simko F. Pathophysiological principles of the relation between myocardial hypertrophy of the left ventricle and its regression. Physiol Res 1994 43 : 259 66.
13. Simko F. Left ventricular hypertrophy regression as a process with variable biological implications. Can J Cardiol 1996 12 : 507 51.
14. Simko F. Physiologic and pathologic myocardial hypertrophy: physiologic and pathologic regression of hypertrophy? Med Hypotheses 2002 58 : 11 4.
15. Friddle CJ, Koga T, Rubin EM, Bristow J. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertophy. Proc Natl Acad Sci USA 2000 97 : 6745 50.
16. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992 5 : 95 110.
17. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996 275 : 1507 13.
18. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003 115 : 41 6.
19. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359 : 995 1003.
20. Packer M. The impossible task of developing a new treatment for heart failure. J Card Fail 2002 8 : 193 6.
21. The Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 339 : 1349 57.
22. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart diseases: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 : 1383 9.
23. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 27 : 1615 22.
24. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Mc Farlane PW et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 333 : 1301 7.
25. Sever PS, Dahlof B, Poulter NR, Wedwel H, Beewera G, Caulfield M et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 361 : 1149 58.
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 7 22.
27. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001 285 : 1711 8.
28. Halcox JP, Deanfield JE. Beyond the laboratory. Clinical implications for statin pleiotropy. Circulation 2004 109 (Suppl. II II 42 8.
29. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004 109 (Suppl. III iii 39 43.
30. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002 87 : 1451 8.
31. Futterman LG, Lemberg L. Statin pleiotropy: fact or fiction? Am J Crit Care 2004 3 : 244 9.
32. Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler Suppl 2006 7 : 31 5.
33. Nakagami H, Jensen KS, Liao JK. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med 2003 35 : 398 403.
34. Nakagami H, Liao JK. Statins and myocardial hypertrophy. Coron Artery Dis 2004 15 : 247 50.
35. Liao JK. Statin therapy for cardiac hypertrophy and heart failure. J Investig Med 2004 52 : 248 53.
36. Laufs U, Böhm M. Cardiac effects of statins - advancements and open questions. Cardiovasc Res 2005 66 : 427 9.
37. Folkeringa RJ, Van Kraaij DJ, Tieleman RG, Nieman FH, Pinto YM, Crijns HJ. Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail 2006 12 : 134 8.
38. Harst P, Voors AA, Gilst WH, Böhm M, Veldhuisen DJ. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 2006 71 : 443 54.
39. Kurian KC, Rai P, Sankaran S, Jacob B, Chiong J, Miller AB. The effect of statins in heart failure: beyond its cholesterol-lowering effect. J Cardiac Fail 2006 12 : 473 8.
40. Laufs U, Custodis F, Bohm M. HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk. Drugs 2006 66 : 145 54.
41. Ramasubbu K, Mann DL. The emerging role of statins in the treatment of heart failure. J Am Coll Cardiol 2006 47 : 332 8.
42. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001 108 : 1429 37.
43. Luo JD, Xie F, Zhang WW, Ma XD, Guan JX, Chen X. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br J Pharmacol 2001 132 : 159 64.
44. Nishikimi T, Tadokoro K, Wang X, Mori Z, Asakawa H, Akimoto K et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin. Eur J Pharmacol 2002 453 : 175 81.
45. Melchert RB, Liu H, Granberry MC, Kennedy RH. Lovastatin inhibits phenyleprine-induced ERK activation and growth of cardiac. Cardiovasc Toxicol 2001 1 : 237 52.
46. Wu L, Zhao L, Zheng Q, Shang F, Wang X, Wang L et al. Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes. Mol Cell Biochem 2006 284 : 65 71.
47. Hu TP, Xu FP, Li YJ, Luo JD. Simvastatin inhibits leptin-induced hypertrophy in cultured neonatal rat cardiomyocytes. Acta Pharmacol Sin 2006 27 : 419 22.
48. Luo JD, Zhang WW, Zhang GP, Guan JX, Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 1999 26 : 903 8.
49. Indolfi C, Di Lorenzo E, Perrino C, Stingone AM, Curcio A, Torella D et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibitis p21ras activation. Circulation 2002 106 : 2118 24.
50. Planavila A, Laguna JC, Vazquez-Carrera M. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochim Biophys Acta 2005 1687 : 76 83.
51. Chen MS, Xu FP, Wang YZ, Zhang GP, Yi Q, Zhang HQ et al. Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis. J Mol Cell Cardiol 2004 37 : 889 96.
52. Nadruz W Jr., Lagosta VJ, Moreno H Jr., Coelho OR, Franchini KG. Simvastatin prevents load-induced protein tyrosine nitration in overloaded hearts. Hypertension 2004 43 : 1060 6.
53. Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 2002 40 : 142 7.
54. Morikawa-Futamatsu K, Adachi S, Maejima Y, Tamamori-Adachi M, Suzuki JI, Ito H et al. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Sci 2006 79 : 1380 90.
55. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001 104 : 317 24.
56. Senthil V, Chen SN, Tsybouleva N, Halder T, Nagueh SF, Willerson JT et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertophic cardiomyopathy. Circ Res 2005 97 : 285 92.
57. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitor. Circulation 2001 104 : 576 81.
58. Dechend R, Fiebeler A, Lindschau C, Bischoff H, Muller D, Park JK et al. Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am J Hypertens 2001 14 (6 Pt 2 55S 61S.
59. Sundstrom J, Lind L, Vessby B, Andren B, Aro A, Lithell H. Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. Circulation 2001 103 : 836 41.
60. ATP channels in hypercholesterolemic rabbits. Atherosclerosis 2004 176 : 273 8.
61. Lee TM, Lin MS, Chou TF, Chang NC. Effect of simvastatin on left ventricular mass in hypercholesterolemic rabbits. Am J Physiol Heart Circ Physiol 2005 288 : H1352 8.
62. Bezerra DG, Mandarim-de-Lacerda CA. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss spontaneously hypertensive rats. Clin Sci 2005 108 : 349 55.
63. Yang L, Gao YJ, Lee RM. The effects of quinapril and atorvastatin on artery structure and function in adult spontaneously hypertensive rats. Eur J Pharmacol 2005 518 : 145 51.
64. Loch D, Levick S, Hoey A, Brown L. Rosuvastatin attenuates hypertension-induced cardiovascular remodelling without affecting blood pressure in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol 2006 47 : 396 404.
65. Hasegawa H, Yamamoto R, Takano H, Mizukami M, Asakawa M, Nagai T et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003 35 : 953 60.
66. Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Nishizawa T et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 2006 47 : 770 9.
67. Ichihara S, Noda A, Nagata K, Obata K, Xu J, Ichihara G et al. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc Res 2006 69 : 726 35.
68. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodelling and failure after experimental myocardial infarction. Circulation 2002 105 : 868 73.
69. Lee TM, Lin MS, Chou TF, Chang NC. Additive effects of combined blockade of AT1 receptor and HMG-CoA-reductase on left ventricular remodelling in infarcted rats. Am J Physiol Heart Circ Physiol 2006 29 : H1281 9.
70. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxid synthase. Circulation 2004 110 : 1933 9.
71. Bernatova I, Pechanova O, Simko F. Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats. Physiol Res 1996 45 : 311 7.
72. Endres M, Laufs U. Effects of statin on endothelium and signaling mechanisms. Stroke 2004 35 (Suppl. 1 2708 11.
73. Nahrendorf M, Hu K, Hiller KH, Galuppo P, Fracarollo D, Schweizer G et al. Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodelling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study. J Am Coll Cardiol 2002 40 : 1695 700.
74. Bliznakov EG. Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Bayol case - a modern Pandora's box. Biomed Pharmacother 2002 56 : 56 9.
75. Kucharska J, Braunova Z, Ulicna O, Zlatos L, Gvozdjakova A. Deficit of coenzyme Q in heart and liver mitochondria of rats with streptozotocin-induced diabetes. Physiol Res 2000 49 : 411 8.
76. Su SF, Hsiao CL, Chu CW, Lee BC, Lee TM. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am J Cardiol 2000 86 : 514 8.
77. Lee TM, Chou TF, Tsai CH. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin f2alpha formation. J Cardiovasc Pharmacol 2002 40 : 868 74.
78. Zhang GG, Zhang SD. Effect of simvastatin on cardiac fibrosis in patients with essential hypertension. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2005 30 : 280 2.
79. Brilla CG. Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc Res 2000 46 : 324 31.
80. Huber D, Brimm J, Koch R, Krayenbuehl HP. Determinants of ejection performance in aortic stenosis. Circulation 1981 64 : 126 34.
81. Karam R, Healy BP, Wicker P. Coronary reserve is depressed in postmyocardial infarction reactive cardiac hypertrophy. Circulation 1990 81 : 238 46.
82. Bernatova I, Pechanova O, Pelouch V, Simko F. Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. J Mol Cell Cardiol 2000 32 : 177 85.
83. Simko F. Spontaneous regression of left ventricular hypertrophy in a rabbit model of aortic insufficiency: possible clinical implications. Med Hypotheses 1995 45 : 556 8.
84. Zähringer J. [Regression of biochemical changes in heart muscle hypertrophy]. Z Kardiol 1985 74 : 119 26.
85. Krayenbuehl HP, Hess OM, Schneider J, Turina M. Rückbildung der Herzhypertrophie bei Patienten mit Operierten Aortenklappenfehlern. Z Kardiol 1985 74 : 145 52.
86. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989 13 : 1637 52.
87. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991 83 : 1849 65.
88. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998 16 : 1031 41.
89. Dzau VJ. Autocrine and paracrine mechanisms in the pathophysiology of heart failure. Am J Cardiol 1992 70 : 4C 11C.
90. Simko F, Luptak I, Matuskova J, Babal P, Pechanova O, Bernatova I et al. Heart remodelling in the hereditary hypertriglyceridemic (hHTG) rat: effect of captopril and nitric oxide deficiency. Ann N Y Acad Sci 2002 967 : 454 62.
91. Simko F, Pelouch V, Torok J, Luptak I, Matuskova J, Pechanova O et al. Protein remodelling of the heart ventricles in hereditary hypertriglyceridemic rat: effect of ACE-inhibition. J Biomed Sci 2005 12 : 103 11.
92. Reddy R, Chahoud G, Mehta JL. Modulation of cardiovascular remodelling with statins: fact or fiction? Curr Vasc Pharmacol 2005 3 : 69 79.
93. Frohlich ED. Overview of hemodynamic and non-hemodynamic factors associated with left ventricular hypertrophy. J Mol Cell Cardiol 1989 21 (Suppl. 5 3 10.
94. Simko F, Simko J. The potential role of nitric oxide in the hypertrophic growth of the left ventricle. Physiol Res 2000 49 : 37 46.
95. Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 2003 42 : 1091 7.
96. Borghi C, Veronesi M, Prandin MG, Dormi A, Ambrosioni E. Statins and blood pressure regulation. Curr Hypertens Rep 2001 3 : 281 8.
97. Borghi C, Dormi A, Veronesi M, Immordino V, Ambrosioni E. Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J Clin Hypertens 2002 4 : 277 85.
98. Pelat T, Balligand JL. Statins and hypertension. Semin Vasc Med 2004 4 : 367 75.
99. Blanco-Colio LM, Osende JI, Martin-Ventura JL, Tunon J, Egido J. Statins in hypertensive patients: potential explanations for the ASCOT-LLA study results. Drugs 2004 64 (Suppl. 2 61 7.
100. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P et al. Additive effects of simvastatin beyond its effect on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000 30 : 980 7.
101. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999 100 : 2131 4.
102. Ichiki T, Takeda K, Tokunou T, Lino N, Egashira K, Shimokawa H et al. Down regulation of angiotensin II type I receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001 21 : 1896 901.
103. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999 34 : 1281 6.
104. Patterson D, Dick JB, Struthers AD. Intensive statin treatment improves baroreflex sensitivity: another cardioprotective mechanism for statins? Heart 2002 88 : 415 6.
105. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003 107 : 2493 8.
106. Milionis HJ, Liberopoulos EN, Achimastos A, Elisaf MS, Mikhailidis DP. Statins: another class of antihypertensive agents? J Hum Hypertens 2006 20 : 320 5.
107. Simko F, Simko J. Heart failure and angiotensin converting enzyme inhibition: problems and perspectives. Physiol Res 1999 48 : 1 8.
108. Kolpakov V, Gordon V, Kulik TJ. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res 1995 76 : 305 9.
109. Recchia FA, McConnell PI, Loke KE, Xu X, Ochoa M, Hintze TH. Nitric oxide controls cardiac substrate utilization in the conscious dog. Cardiovasc Res 1999 44 : 325 32.
110. Sharman JE, Fang ZY, Haluska B, Stowasser M, Prins JB, Marwick TH. Left ventricular mass in patients with type 2 diabetes is independently associated with central but not peripheral pulse pressure. Diabetes Care 2005 28 : 937 9.
111. Saba PS, Roman MJ, Pini R, Spitzer M, Ganau A, Devereux RB. Relation of arterial pressure waveform to left ventricular and carotid anatomy in normotensive subjects. J Am Coll Cardiol 1993 22 : 1873 80.
112. Marchais SJ, Guerin AP, Pannier BM, Levy BI, Safar ME, London GM. Wave reflections and cardiac hypertrophy in chronic uremia. Influence of body size. Hypertension 1993 22 : 876 83.
113. Hashimoto J, Watabe D, Hatanaka R, Hanasawa T, Metoki H, Asayama K et al. Enhanced radial late systolic pressure augmentation in hypertensive patients with left ventricular hypertrophy. Am J Hypertens 2006 19 : 27 32.
114. Lekakis JP, Zakopoulos NA, Protogerou AD, Kotsis VT, Papaioannou TG, Stamatelopoulos KS et al. Cardiac hypertrophy in hypertension: relation to 24-h blood pressure profile and arterial stiffness. Int J Cardiol 2004 97 : 29 33.
115. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002 39 : 1020 5.
116. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 2006 31 : 730 42.
117. Mital S, Liao JK. Statins and the myocardium. Semin Vasc Med 2004 4 : 377 84.
118. Luo JD, Chen AF. Perspectives on the cardioprotective effect of statins. Curr Med Chem 2003 10 : 1593 601.
119. Gregg D, Rauscher FM, Goldschmidt-Clermont PJ. Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. Am J Physiol Cell Physiol 2003 285 : C723 34.
120. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai J, Morikawa K et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD (P) H oxidase system. Circ Res 2003 93 : 767 75.
121. Aoki H, Izumo S, Sadoshima J. Angiotensin II activates RhoA in cardiac myocytes: a critical role of Rho A in angiotensin II-induced premyofibril formation. Circ Res 1998 82 : 666 76.
122. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, Mc Murray JV et al. CORONA Study Group: a statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005 7 : 1059 69.
123. Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R et al. GISSI-HF Investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004 6 : 635 41.